Cl-1033, a pan-erbB tyrosine kinase inhibitor

被引：76

作者：

Slichenmyer, WJ ^{[1
]}

Elliott, WL ^{[1
]}

Fry, DW ^{[1
]}

机构：

[1] Pfizer Global Res & Dev, Dept Canc Res, Ann Arbor, MI 48105 USA

来源：

SEMINARS IN ONCOLOGY | 2001年 / 28卷 / 05期

关键词：

D O I：

10.1016/S0093-7754(01)90285-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：80 / 85

页数：6

共 19 条

[1] The ErbB receptors as targets for breast cancer therapy [J].

Albanell, J ;

Baselga, J .

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1999, 4 (04) :337-351

[2] Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes [J].

Amundadottir, LT ;

Leder, P .

ONCOGENE, 1998, 16 (06) :737-746

[3]

BACUS SS, 1994, AM J CLIN PATHOL S1, V102, P13

[4] The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer [J].

Bartlett, JMS ;

Langdon, SP ;

Simpson, BJB ;

Stewart, M ;

Katsaros, D ;

Sismondi, P ;

Love, S ;

Scott, WN ;

Williams, ARW ;

Lessells, AM ;

Macleod, KG ;

Smyth, JF ;

Miller, WR .

BRITISH JOURNAL OF CANCER, 1996, 73 (03) :301-306

[5]

Baselga J, 1999, SEMIN ONCOL, V26, P78

[6]

Baselga J, 1998, CANCER RES, V58, P2825

[7] Targeting the epidermal growth factor receptor for therapy of carcinomas [J].

Davies, DE ;

Chamberlin, SG .

BIOCHEMICAL PHARMACOLOGY, 1996, 51 (09) :1101-1110

[8] Dominance of ErbB-1 heterodimers in lung epithelial cells overexpressing ErbB-2 - Both ErbB-1 and ErbB-2 contribute significantly to tumorigenicity [J].

Fernandes, AM ;

Hamburger, AW ;

Gerwin, BI .

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1999, 21 (06) :701-709

[9]

Fry DW, 2000, ANTI-CANCER DRUG DES, V15, P3

[10] Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors [J].

Fry, DW .

PHARMACOLOGY & THERAPEUTICS, 1999, 82 (2-3) :207-218

← 1 2 →